SAS can help life sciences companies gain deeper insights by providing line-of-business analysts in R and D, sales, marketing, and regulatory affairs the ability to blend and analyze data themselves, without any coding or IT dependence. Expiring patents, increasing drug-development costs, outcome-based reimbursement models, and more stringent regulations are all driving life sciences companies to reassess their business models and rethink their approaches to R&D, pricing, and sales and marketing. Pharma and biotech executives looking for ways to reduce costs, improve efficiency, increase ROI, and mitigate risks are leaning on already overwhelmed IT departments for faster, more reliable evidence-based insights. 

SAS's emphasis on making data science accessible to citizen data scientists and others across the end-to-end analytic pipeline is resonating in the market. Its approach provides a natural extension for a client base focused on data preparation but ready to take the next step into data science.